Introduction: Dementia is among the costliest of medical conditions, but it is not known how these costs vary by dementia subtype. Methods: The effect of dementia diagnosis subtype on direct health care costs and utilization was estimated using 2015 California Medicare fee-for-service data. Potential drivers of increased costs in Lewy body dementia (LBD), in comparison to Alzheimer's disease, were tested. Results: 3,001,987 Medicare beneficiaries were identified, of which 8.2% had a dementia diagnosis. Unspecified dementia was the most common diagnostic category (59.6%), followed by Alzheimer's disease (23.2%). LBD was the costliest subtype to Medicare, on average, followed by vascular dementia. The higher costs in LBD were explained in part by falls, urinary incontinence or infection, depression, anxiety, dehydration, and delirium. Discussion: Dementia subtype is an important predictor of health care costs. Earlier identification and targeted treatment might mitigate the costs associated with co-occurring conditions in LBD.
Bibliographical noteFunding Information:
This project was funded by the Global Brain Health Institute , the Department of Health and Human Services , Centers for Medicare & Medicaid Services ( 1C1CMS331346 ), the National Institute on Aging ( 5R01AG056715 ), and the National Institute on Neurological Disorders and Stroke ( UG3 NS105557 ). The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official views of the U.S. Department of Health and Human Services or any of its agencies. None of the funding agencies were involved in study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. The authors are grateful to Sarah Dulaney and Michael Schaffer for their work on project operations and data management.
- Alzheimer's disease
- Health care costs
- Lewy body dementia
- Vascular dementia